AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 8458180 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 x 12.5 mg levoleucovorin tablet
Number of subjects: 68
Study 8458180 — intervention group
Group type: COMPARATOR
Intervention: 1 x 25 mg leucovorin tablet
Number of subjects: 68
Study 8458180 — intervention group
Group type: EXPERIMENTAL
Intervention: 15 mg levoleucovorin injection
Number of subjects: 68
Study 8458180 — intervention group
Group type: COMPARATOR
Intervention: 2 x 7.5 mg levoleucovorin tablets
Number of subjects: 68
Study 8458180 — intervention group
Group type: EXPERIMENTAL
Intervention: 30 mg leucovorin injection
Number of subjects: 68
Study 8458180 — intervention group
Group type: COMPARATOR
Intervention: 2 x 15 mg leucovorin tablets
Number of subjects: 68
Study 3510686 — intervention group
Group type: EXPERIMENTAL
Intervention: Piroxicam
Number of subjects: 47
Study 3510686 — intervention group
Group type: COMPARATOR
Intervention: Naproxen
Number of subjects: 47
Study 29771814 — intervention group
Group type: EXPERIMENTAL
Intervention: Simulation arm (interactive video simulations)
Number of subjects: 0
Study 29771814 — intervention group
Group type: COMPARATOR
Intervention: Education-as-usual arm (control)
Number of subjects: 0
Study 26104969 — intervention group
Group type: EXPERIMENTAL
Intervention: losartan 50mg qd
Number of subjects: 72
Study 26104969 — intervention group
Group type: COMPARATOR
Intervention: β-blocker bisoprolol 5mg qd
Number of subjects: 72
Study 24721892 — intervention group
Group type: EXPERIMENTAL
Intervention: In-center daily hemodialysis (6 days/week)
Number of subjects: 332
Study 24721892 — intervention group
Group type: EXPERIMENTAL
Intervention: Home nocturnal hemodialysis (6 nights/week)
Number of subjects: 332
Study 24721892 — intervention group
Group type: COMPARATOR
Intervention: Home conventional hemodialysis
Number of subjects: 332
Study 24721892 — intervention group
Group type: COMPARATOR
Intervention: In-center conventional hemodialysis (3 days/week)
Number of subjects: 332
Study 22934153 — intervention group
Group type: COMPARATOR
Intervention: Albendazole or Praziquantel (placebo)
Number of subjects: 0
Study 22934153 — intervention group
Group type: EXPERIMENTAL
Intervention: Albendazole and Praziquantel
Number of subjects: 0
Study 22934153 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (Albendazole/Praziquantel and placebo)
Number of subjects: 0
Study 20304351 — intervention group
Group type: EXPERIMENTAL
Intervention: PEEP 15 cm H(2)O
Number of subjects: 74
Study 20304351 — intervention group
Group type: COMPARATOR
Intervention: PEEP 5 cm H(2)O
Number of subjects: 74
Study 18362486 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluoxetine 90 mg plus Tadalafil 20 mg
Number of subjects: 60
Study 18362486 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluoxetine 90 mg
Number of subjects: 60
Study 18362486 — intervention group
Group type: EXPERIMENTAL
Intervention: Tadalafil 20 mg
Number of subjects: 60
Study 18362486 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study 15809403 — intervention group
Group type: EXPERIMENTAL
Intervention: Olanzapine (5-20 mg/d)
Number of subjects: 263
Study 15809403 — intervention group
Group type: COMPARATOR
Intervention: Haloperidol (2-20 mg/d)
Number of subjects: 263
Study 15809403 — intervention group
Group type: COMPARATOR
Intervention: Healthy volunteers (n = 58)
Number of subjects: 263
Study 12207593 — intervention group
Group type: EXPERIMENTAL
Intervention: Nurse follow-up clinic
Number of subjects: 0
Study 12207593 — intervention group
Group type: COMPARATOR
Intervention: Normal care
Number of subjects: 0
Study 10216796 — intervention group
Group type: EXPERIMENTAL
Intervention: Blood pressure control and angiotensin-converting enzyme (ACE) inhibitors
Number of subjects: 0
Study 10216796 — intervention group
Group type: EXPERIMENTAL
Intervention: Partial correction of anemia with iron, erythropoietin, or androgens
Number of subjects: 0
Study 10216796 — intervention group
Group type: EXPERIMENTAL
Intervention: Early dietary phosphate restriction, use of calcium-containing phosphate binders, and activated vitamin D
Number of subjects: 0
Study 10216796 — intervention group
Group type: EXPERIMENTAL
Intervention: Correction of acidosis
Number of subjects: 0
Study 10216796 — intervention group
Group type: EXPERIMENTAL
Intervention: Treatment of hyperlipidemia
Number of subjects: 0
Study 10216796 — intervention group
Group type: EXPERIMENTAL
Intervention: Early involvement of a nephrology-based multidisciplinary team
Number of subjects: 0
Study 7798084 — intervention group
Group type: EXPERIMENTAL
Intervention: Structured Clinical Interview for DSM‐III‐R Personality Disorders (SCID)
Number of subjects: 100
Study 7798084 — intervention group
Group type: COMPARATOR
Intervention: Nonstructured psychiatric interviews
Number of subjects: 100
Study 2205447 — intervention group
Group type: EXPERIMENTAL
Intervention: 3% sodium lauryl sulfate
Number of subjects: 9
Study 431401 — intervention group
Group type: EXPERIMENTAL
Intervention: C+A (Carbenicillin + Amikacin)
Number of subjects: 281
Study 431401 — intervention group
Group type: EXPERIMENTAL
Intervention: C+G (Carbenicillin + Gentamicin)
Number of subjects: 281
Study 431401 — intervention group
Group type: EXPERIMENTAL
Intervention: C+S (Carbenicillin + Sisomicin)
Number of subjects: 281
Study 431401 — intervention group
Group type: EXPERIMENTAL
Intervention: All groups (C+A, C+G, C+S)
Number of subjects: 281
Study 431401 — intervention group
Group type: EXPERIMENTAL
Intervention: Klebsiella spp. (pathogen)
Number of subjects: 281
Study 431401 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with persistent severe neutropenia
Number of subjects: 281
Study 30514879 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous Energy Restriction (CER)
Number of subjects: 98
Study 30514879 — intervention group
Group type: COMPARATOR
Intervention: Intermittent Energy Restriction (IER)
Number of subjects: 98
Study 29749328 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral vitamin E (400 mg/day)
Number of subjects: 80
Study 29749328 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral UDCA (15 mg/kg/day)
Number of subjects: 80
Study 29749328 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of vitamin E and UDCA
Number of subjects: 80
Study 29749328 — intervention group
Group type: COMPARATOR
Intervention: Control group (no drug except chemotherapy)
Number of subjects: 80
Study 27156561 — intervention group
Group type: COMPARATOR
Intervention: Tofacitinib 1-15 mg BID, 20 mg QD
Number of subjects: 891
Study 27156561 — intervention group
Group type: COMPARATOR
Intervention: Tofacitinib 1-15 mg BID
Number of subjects: 891
Study 27156561 — intervention group
Group type: COMPARATOR
Intervention: Tofacitinib
Number of subjects: 891
Study 25135737 — intervention group
Group type: EXPERIMENTAL
Intervention: Endoscopic retrograde cholangiopancreatography (ERCP) in liver cirrhotic patients
Number of subjects: 46
Study 25135737 — intervention group
Group type: EXPERIMENTAL
Intervention: Endoscopic retrograde cholangiopancreatography (ERCP) in Child-Pugh C patients
Number of subjects: 46
Study 25135737 — intervention group
Group type: COMPARATOR
Intervention: Endoscopic retrograde cholangiopancreatography (ERCP) in non-cirrhotic patients
Number of subjects: 46
Study 22252804 — intervention group
Group type: EXPERIMENTAL
Intervention: Dihydroartemisinin-piperaquine monthly (DPm)
Number of subjects: 1000
Study 22252804 — intervention group
Group type: EXPERIMENTAL
Intervention: Dihydroartemisinin-piperaquine every 2 months (DPalt)
Number of subjects: 1000
Study 22252804 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1000
Study 20446828 — intervention group
Group type: EXPERIMENTAL
Intervention: Unrestricted postoperative weight bearing
Number of subjects: 38
Study 20446828 — intervention group
Group type: COMPARATOR
Intervention: Partial weight bearing for 3 months
Number of subjects: 38
Study 17161997 — intervention group
Group type: EXPERIMENTAL
Intervention: Use of recommended questionnaires for urinary incontinence
Number of subjects: 150
Study 17161997 — intervention group
Group type: EXPERIMENTAL
Intervention: Use of recommended questionnaires for anal incontinence
Number of subjects: 150
Study 17161997 — intervention group
Group type: COMPARATOR
Intervention: Use of recommended questionnaires for vaginal and pelvic floor problems
Number of subjects: 150
Study 15653941 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluoxetine (20 mg‐60 mg/day)
Number of subjects: 90
Study 15653941 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 90
Study 11920997 — intervention group
Group type: EXPERIMENTAL
Intervention: Low WHR images selected by high WHR group
Number of subjects: 2
Study 11920997 — intervention group
Group type: EXPERIMENTAL
Intervention: Low WHR images selected by low WHR group
Number of subjects: 2
Study 9818845 — intervention group
Group type: EXPERIMENTAL
Intervention: Diastat (diazepam rectal gel)
Number of subjects: 158
Study 9818845 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 158
Study 7656471 — intervention group
Group type: EXPERIMENTAL
Intervention: L-fucose in RA patients
Number of subjects: 135
Study 7656471 — intervention group
Group type: COMPARATOR
Intervention: Healthy controls
Number of subjects: 135
Study 7656471 — intervention group
Group type: EXPERIMENTAL
Intervention: Early RA patients
Number of subjects: 135
Study 7656471 — intervention group
Group type: EXPERIMENTAL
Intervention: Advanced RA patients
Number of subjects: 135
Study 7656471 — intervention group
Group type: EXPERIMENTAL
Intervention: Female advanced RA patients
Number of subjects: 135
Study 7656471 — intervention group
Group type: EXPERIMENTAL
Intervention: Male advanced RA patients
Number of subjects: 135
Study 7656471 — intervention group
Group type: EXPERIMENTAL
Intervention: Female early RA patients
Number of subjects: 135
Study 7656471 — intervention group
Group type: EXPERIMENTAL
Intervention: Male early RA patients
Number of subjects: 135
Study 7656471 — intervention group
Group type: EXPERIMENTAL
Intervention: Correlation with disease activity
Number of subjects: 135
Study 7656471 — intervention group
Group type: EXPERIMENTAL
Intervention: Seropositive vs seronegative RA patients
Number of subjects: 135
Study 2669002 — intervention group
Group type: EXPERIMENTAL
Intervention: Acetazolamide and thiamine (A + T)
Number of subjects: 24
Study 2669002 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study 786422 — intervention group
Group type: EXPERIMENTAL
Intervention: Flurbiprofen 150 mg daily for 5 days
Number of subjects: 52
Study 786422 — intervention group
Group type: COMPARATOR
Intervention: Soluble aspirin 3.6 g daily for 5 days
Number of subjects: 52
Study 6773484 — intervention group
Group type: EXPERIMENTAL
Intervention: Parenteral amino acids
Number of subjects: 0
Study 6773484 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypertonic glucose plus amino acids
Number of subjects: 0
Study 6773484 — intervention group
Group type: COMPARATOR
Intervention: No hyperalimentation
Number of subjects: 0
Study 31774526 — intervention group
Group type: EXPERIMENTAL
Intervention: Waist circumference
Number of subjects: 2755
Study 31774526 — intervention group
Group type: EXPERIMENTAL
Intervention: Waist-to-hip ratio (WHR)
Number of subjects: 2755
Study 31774526 — intervention group
Group type: EXPERIMENTAL
Intervention: Body mass index (BMI)
Number of subjects: 2755
Study 29255190 — intervention group
Group type: COMPARATOR
Intervention: Immediate cord clamping (ICC) within 15 seconds
Number of subjects: 720
Study 29255190 — intervention group
Group type: EXPERIMENTAL
Intervention: Delayed cord clamping (DCC) by 30 seconds
Number of subjects: 720
Study 29255190 — intervention group
Group type: EXPERIMENTAL
Intervention: Delayed cord clamping (DCC) by 60 seconds
Number of subjects: 720
Study 29255190 — intervention group
Group type: EXPERIMENTAL
Intervention: Delayed cord clamping (DCC) by 90 seconds
Number of subjects: 720
Study 29255190 — intervention group
Group type: EXPERIMENTAL
Intervention: Delayed cord clamping (DCC) by 120 seconds
Number of subjects: 720
Study 29255190 — intervention group
Group type: EXPERIMENTAL
Intervention: Delayed cord clamping (DCC) by 150 seconds
Number of subjects: 720
Study 29255190 — intervention group
Group type: EXPERIMENTAL
Intervention: Delayed cord clamping (DCC) by 180 seconds
Number of subjects: 720
Study 29255190 — intervention group
Group type: EXPERIMENTAL
Intervention: Delayed cord clamping (DCC) when umbilical cord pulsation ceased
Number of subjects: 720
Study 26818528 — intervention group
Group type: EXPERIMENTAL
Intervention: Anodal tDCS
Number of subjects: 120
Study 26818528 — intervention group
Group type: COMPARATOR
Intervention: Sham tDCS
Number of subjects: 120
Study 26818528 — intervention group
Group type: COMPARATOR
Intervention: Cathodal tDCS
Number of subjects: 120
Study 24456339 — intervention group
Group type: EXPERIMENTAL
Intervention: Carbohydrate-enriched night meal (20-30% increase in carbohydrates during the second week)
Number of subjects: 54
Study 24456339 — intervention group
Group type: EXPERIMENTAL
Intervention: Protein-enriched night meal (30-40% increase in protein during the third week)
Number of subjects: 54
Study 24456339 — intervention group
Group type: COMPARATOR
Intervention: No change in food composition (first week)
Number of subjects: 54
Study 22215654 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous glucose (delivered intragastrically)
Number of subjects: 0
Study 22215654 — intervention group
Group type: COMPARATOR
Intervention: Intraduodenal glucose infusion (3 kcal/min)
Number of subjects: 0
Study 22215654 — intervention group
Group type: EXPERIMENTAL
Intervention: Mixed liquid meal (delivered intragastrically)
Number of subjects: 0
Study 21284343 — intervention group
Group type: EXPERIMENTAL
Intervention: High dose of arginine (20 g per day)
Number of subjects: 115
Study 21284343 — intervention group
Group type: COMPARATOR
Intervention: Medium dose of arginine (12.3 g per day)
Number of subjects: 115
Study 17714986 — intervention group
Group type: EXPERIMENTAL
Intervention: One painful clip applied to the earlobe
Number of subjects: 19
Study 17714986 — intervention group
Group type: EXPERIMENTAL
Intervention: One painful clip applied to the nostril
Number of subjects: 19
Study 17714986 — intervention group
Group type: EXPERIMENTAL
Intervention: Four painful clips applied simultaneously to the earlobe, nostril, eyebrow, and lower lip
Number of subjects: 19
Study 16274036 — intervention group
Group type: EXPERIMENTAL
Intervention: Perioperative nutrition support (enteral and parenteral nutrition)
Number of subjects: 82
Study 16274036 — intervention group
Group type: COMPARATOR
Intervention: Routine postoperative parenteral nutrition
Number of subjects: 82
Study 16274036 — intervention group
Group type: EXPERIMENTAL
Intervention: Perioperative nutrition support (enteral and parenteral nutrition) in PD subgroup
Number of subjects: 82
Study 16274036 — intervention group
Group type: COMPARATOR
Intervention: Routine postoperative parenteral nutrition in PD subgroup
Number of subjects: 82
Study 11964588 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexamethasone 1 mg/kg-1 after induction of anesthesia
Number of subjects: 20
Study 11964588 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified in detail)
Number of subjects: 20
Study 9466469 — intervention group
Group type: EXPERIMENTAL
Intervention: Allopurinol (300 mg orally, 12 and 2 hours before ischemia)
Number of subjects: 0
Study 9466469 — intervention group
Group type: EXPERIMENTAL
Intervention: Indomethacin (50 mg orally, 2 hours before ischemia)
Number of subjects: 0
Study 9466469 — intervention group
Group type: COMPARATOR
Intervention: Tourniquet arm (ischemia)
Number of subjects: 0
Study 9466469 — intervention group
Group type: COMPARATOR
Intervention: Control arm (no ischemia)
Number of subjects: 0
Study 7623370 — intervention group
Group type: EXPERIMENTAL
Intervention: Hawksley random‐zero sphygmomanometer
Number of subjects: 65
Study 7623370 — intervention group
Group type: COMPARATOR
Intervention: Standard mercury sphygmomanometer
Number of subjects: 65
Study 2649141 — intervention group
Group type: EXPERIMENTAL
Intervention: Mild induction and intensive consolidation therapy
Number of subjects: 358
Study 2649141 — intervention group
Group type: COMPARATOR
Intervention: Mild post consolidation treatment
Number of subjects: 358
Study 2649141 — intervention group
Group type: EXPERIMENTAL
Intervention: CNS prophylaxis with intrathecal chemotherapy and intermediate dose i.v. methotrexate (MTX) and cytosine arabinoside (ARA-C)
Number of subjects: 358
Study 333515 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral prostaglandin E2 (10 tablets given on an hourly regime)
Number of subjects: 48
Study 333515 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 48
Study 31067324 — intervention group
Group type: EXPERIMENTAL
Intervention: QH treatments in specialist orthodontic clinics (QHS)
Number of subjects: 110
Study 31067324 — intervention group
Group type: EXPERIMENTAL
Intervention: QH treatments in general dentistry (QHG)
Number of subjects: 110
Study 31067324 — intervention group
Group type: EXPERIMENTAL
Intervention: EP treatments in specialist orthodontic clinics (EPS)
Number of subjects: 110
Study 31067324 — intervention group
Group type: EXPERIMENTAL
Intervention: EP treatments in general dentistry (EPG)
Number of subjects: 110
Study 29036391 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive-Behavioral Social Skills Training (CBSST)
Number of subjects: 149
Study 27740929 — intervention group
Group type: EXPERIMENTAL
Intervention: 11.25- or 30-mg 3-month leuprolide acetate (LA)
Number of subjects: 42
Study 27740929 — intervention group
Group type: EXPERIMENTAL
Intervention: Basal LH levels
Number of subjects: 42
Study 27740929 — intervention group
Group type: EXPERIMENTAL
Intervention: 3-month leuprolide acetate treatments
Number of subjects: 42
Study 27740929 — intervention group
Group type: EXPERIMENTAL
Intervention: Basal LH < 0.60 IU/L
Number of subjects: 42
Study 25156340 — intervention group
Group type: EXPERIMENTAL
Intervention: Cardiovascular screening and exercise tolerance test prior to rehabilitation
Number of subjects: 408
Study 25156340 — intervention group
Group type: EXPERIMENTAL
Intervention: Negative cardiac screen and absence of exercise tolerance test failure
Number of subjects: 408
Study 22257506 — intervention group
Group type: EXPERIMENTAL
Intervention: Home-based treadmill training (20-40 minutes, four times a week for six weeks)
Number of subjects: 20
Study 22257506 — intervention group
Group type: EXPERIMENTAL
Intervention: Home-based treadmill training
Number of subjects: 20
Study 22257506 — intervention group
Group type: COMPARATOR
Intervention: Control group (usual care)
Number of subjects: 20
Study 19327317 — intervention group
Group type: EXPERIMENTAL
Intervention: Carbohydrate-restrictive strategy (group 1)
Number of subjects: 337
Study 19327317 — intervention group
Group type: COMPARATOR
Intervention: Intensive insulin therapy (group 2)
Number of subjects: 337
Study 17973956 — intervention group
Group type: EXPERIMENTAL
Intervention: Valacyclovir (2 g q.i.d.)
Number of subjects: 70
Study 17973956 — intervention group
Group type: COMPARATOR
Intervention: Valganciclovir (900 mg b.i.d. for a minimum of 14 days)
Number of subjects: 70
Study 16163870 — intervention group
Group type: EXPERIMENTAL
Intervention: D/Sense 2
Number of subjects: 60
Study 16163870 — intervention group
Group type: EXPERIMENTAL
Intervention: Seal & Protect 2.0
Number of subjects: 60
Study 16163870 — intervention group
Group type: EXPERIMENTAL
Intervention: Gluma Desensitizer
Number of subjects: 60
Study 16163870 — intervention group
Group type: COMPARATOR
Intervention: Control (untreated)
Number of subjects: 60
Study 12965978 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous omeprazole infusion plus endoscopic therapy
Number of subjects: 156
Study 12965978 — intervention group
Group type: COMPARATOR
Intervention: Intravenous omeprazole infusion alone
Number of subjects: 156
Study 10725614 — intervention group
Group type: EXPERIMENTAL
Intervention: Paroxetine (30 mg/day)
Number of subjects: 8
Study 10725614 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8
Study 8729159 — intervention group
Group type: EXPERIMENTAL
Intervention: Dipyridamole thallium imaging
Number of subjects: 93
Study 1551058 — intervention group
Group type: EXPERIMENTAL
Intervention: Breast conservation therapy
Number of subjects: 109
Study 1551058 — intervention group
Group type: COMPARATOR
Intervention: Mastectomy
Number of subjects: 109
Study 1551058 — intervention group
Group type: EXPERIMENTAL
Intervention: Both surgical groups
Number of subjects: 109
Study 3887560 — intervention group
Group type: EXPERIMENTAL
Intervention: Cefadroxil 1 g once daily for 3 days
Number of subjects: 310
Study 3887560 — intervention group
Group type: EXPERIMENTAL
Intervention: Cefadroxil 1 g once daily for 7 days
Number of subjects: 310
Study 3887560 — intervention group
Group type: COMPARATOR
Intervention: Amoxycillin 375 mg t.i.d. for 7 days
Number of subjects: 310
Study 28668204 — intervention group
Group type: EXPERIMENTAL
Intervention: Cisplatin (75 mg/m2, day 1) and Pemetrexed (500 mg/m2, day 1)
Number of subjects: 804
Study 28668204 — intervention group
Group type: COMPARATOR
Intervention: Cisplatin (80 mg/m2, day 1) and Vinorelbine (25 mg/m2, days 1 and 8)
Number of subjects: 804
Study 28668204 — intervention group
Group type: EXPERIMENTAL
Intervention: Cisplatin with Pemetrexed
Number of subjects: 804
Study 28668204 — intervention group
Group type: COMPARATOR
Intervention: Cisplatin with Vinorelbine
Number of subjects: 804
Study 27632271 — intervention group
Group type: EXPERIMENTAL
Intervention: Ceramic inlays
Number of subjects: 28
Study 27632271 — intervention group
Group type: COMPARATOR
Intervention: Composite fillings (control group)
Number of subjects: 28
Study 24447003 — intervention group
Group type: EXPERIMENTAL
Intervention: Telephone-administered cognitive behavioral therapy (T-CBT)
Number of subjects: 325
Study 24447003 — intervention group
Group type: COMPARATOR
Intervention: Face-to-face cognitive behavioral therapy (FtF-CBT)
Number of subjects: 325
Study 24447003 — intervention group
Group type: EXPERIMENTAL
Intervention: Both T-CBT and FtF-CBT
Number of subjects: 325
Study 22905961 — intervention group
Group type: EXPERIMENTAL
Intervention: 5 Cs of Consultation (Contact, Communicate, Core Question, Collaboration, and Closing the Loop) educational session
Number of subjects: 43
Study 22905961 — intervention group
Group type: COMPARATOR
Intervention: Unstructured group
Number of subjects: 43
Study 18616811 — intervention group
Group type: EXPERIMENTAL
Intervention: Single-dose pegfilgrastim 6 mg
Number of subjects: 84
Study 18616811 — intervention group
Group type: COMPARATOR
Intervention: Daily filgrastim 5 mug/kg
Number of subjects: 84
Study 15960931 — intervention group
Group type: EXPERIMENTAL
Intervention: Samarium-153 (Quadramet) therapy
Number of subjects: 0
Study 15960931 — intervention group
Group type: COMPARATOR
Intervention: Conventional therapy
Number of subjects: 0
Study 12610039 — intervention group
Group type: EXPERIMENTAL
Intervention: Acute administration of GLP-1
Number of subjects: 18
Study 12610039 — intervention group
Group type: EXPERIMENTAL
Intervention: 3-h preinfusion of GLP-1
Number of subjects: 18
Study 12610039 — intervention group
Group type: COMPARATOR
Intervention: Control (without GLP-1)
Number of subjects: 18